Clinical Case Reports (Dec 2023)

Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

  • Si‐Man Huang,
  • Chao‐Ling Wan,
  • Han‐Yu Cao,
  • Yan‐Yan Li,
  • Chong‐Sheng Qian,
  • Hai‐Xia Zhou,
  • Ming‐Zhu Xu,
  • Xiao‐Hui Hu,
  • Lan Dai,
  • Hai‐Ping Dai,
  • Sheng‐Li Xue

DOI
https://doi.org/10.1002/ccr3.8289
Journal volume & issue
Vol. 11, no. 12
pp. n/a – n/a

Abstract

Read online

Key Clinical Message There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B‐ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.

Keywords